| Literature DB >> 35942863 |
Zafar Ali Shah1,2, Khalid Khan1, Zafar Iqbal2, Tariq Masood2, Hassan A Hemeg3, Abdur Rauf4.
Abstract
BACKGROUND: Penicillium produces a wide range of structurally diverse metabolites with significant pharmacological impacts in medicine and agriculture. For the first time, a complete metabolome of Penicillium claviforme (P. claviforme) (FBP-DNA-1205) was studied alongside pharmacological research in this study.Entities:
Keywords: Penicillium claviforme; metabolic profiling; molecular docking; pharmacological activities
Mesh:
Substances:
Year: 2022 PMID: 35942863 PMCID: PMC9367661 DOI: 10.1080/07853890.2022.2102205
Source DB: PubMed Journal: Ann Med ISSN: 0785-3890 Impact factor: 5.348
LCMS-QTOF (positive mode) data of P. claviforme.
| S. No | Name | Formula | RT | [M + H] +m/z | Mass |
|---|---|---|---|---|---|
| 1 | Quinoline | C9 H7 N | 2.406 | 130.0653 | 129.058 |
| 2 | N-(6-Oxo-6H-dibenzo[b,d]pyran-3-yl)acetamide | C15 H11 N O3 | 2.516 | 254.0811 | 253.0739 |
| 3 | 5,8-tetradecadienal | C14 H24 O | 15.724 | 226.2169 | 208.1831 |
| 4 | Cetrimonium | C19 H42 N | 16.892 | 284.3316 | 284.3321 |
| 5 | Kurilensoside F | C33 H58 O11 | 17.112 | 648.4319 | 630.3981 |
| 6 | 3β,15β,17α-Trihydroxy-pregnenone | C21 H32 O4 | 21.898 | 719.4498 | 348.2305 |
| 7 | 5S-HETE di-endoperoxide | C20 H34 O8 | 17.565 | 425.2154 | 402.2263 |
| 8 | Obtusin | C18 H16 O7 | 3.039 | 345.0972 | 344.0902 |
| 9 | 4,4′-Diaminostilbene | C14 H14 N2 | 2.965 | 233.105 | 210.1158 |
| 10 | Amobarbital | C11 H18 N2 O3 | 1.942 | 227.1391 | 226.1319 |
| 11 | 4-(Trimethylammonio)but-2-enoate | C7 H14 N O2 | 0.943 | 144.1018 | 144.1024 |
| 12 | Fraxetin | C10 H8 O5 | 3.09 | 209.0445 | 208.0372 |
| 13 | Maculosin | C14 H16 N2 O3 | 2.026 | 261.1235 | 260.1163 |
| 14 | Onchidal | C17 H24 O3 | 15.551 | 277.1803 | 276.1731 |
| 15 | β-Funaltrexamine | C25 H30 N2 O6 | 3.561 | 909.4308 | 454.213 |
| 16 | His Ile Leu | C18 H31 N5 O4 | 16.877 | 780.5102 | 381.2392 |
| 17 | 3-Hydroxybenzyl alcohol | C7 H8 O2 | 2.225 | 125.0601 | 124.0529 |
| 18 | Linoleic acid | C18 H32 O2 | 19.298 | 281.2474 | 280.2401 |
| 19 | Phalluside-1 | C41 H75 N O9 | 24.091 | 726.5343 | 725.5449 |
Figure 1.Metabolomic profiling using LC-MS QTOF (ESI+), the chromatogram of ethyl acetate extract of P. claviforme presenting molecular masses for different compounds.
Data obtained from GCMS spectrum of P. claviforme.
| Retention time (minutes) | Area (Ab*s) | Match name | Molecular weight (amu) |
|---|---|---|---|
| 26.053 | 19248287 | 1-Octadecene | 252.282 |
| 28.79 | 10713339 | Hexadecanoic acid, methyl ester | 270.256 |
| 31.966 | 36914343 | 9,12-Octadecadienoic acid (Z,Z)-, methyl ester | 294.256 |
| 21.675 | 9742818 | 1-Hexadecene | 224.25 |
| 30.034 | 39221462 | E-14-Hexadecenal | 238.23 |
| 49.664 | 81708468 | 12-Oleanen-3-yl acetate, (3.alpha.) | 468.397 |
| 16.832 | 1749715 | 1-Tetradecene | 196.219 |
| 25.782 | 8359480 | Benzyl Benzoate | 212.084 |
| 1-Nonadecene | 266.297 | ||
| 29.603 | 9403164 | 1,2-Benzenedicarboxylic acid, butyl 2-methylpropyl ester | 278.152 |
| Behenic alcohol | 326.355 | ||
| 1-Heneicosanol | 312.339 | ||
| 33.675 | 40093240 | 1-Docosene | 308.344 |
| 3-Eicosene, (E) | 280.313 | ||
| 37.025 | 2.5E + 08 | Cyclotetracosane | 336.376 |
| Propofol | 178.136 | ||
| 1-Hexadecanol | 242.261 | ||
| 1-Heptadecene | 238.266 | ||
| 1-Pentadecene | 210.235 | ||
| n-Nonadecanol-1 | 284.308 | ||
| 11-Tricosene | 322.36 | ||
| n-Tetracosanol-1 | 354.386 | ||
| Cycloeicosane | 280.313 | ||
| 32.689 | 1923942 | Eicosane | 282.329 |
| 2(1H)Naphthalenone, 3,5,6,7,8,8a-hexahydro-4,8a-dimethyl-6-(1-methylethenyl)- | 218.167 |
Figure 2.GCMS chromatogram of P. claviforme.
Figure 3.Percent mortality of Ethyl acetate and n-hexane extract of P. claviforme.
Percent mortality of extracts of ethyl acetate and n-hexane.
| Dose (µgml−1) | % Mortality | ||
|---|---|---|---|
| Ethyl acetate | n-Hexane | Negative control | |
| 100 | 45 ± 0.42 c | 50 ± 0.63 c | 0 |
| 500 | 70 ± 0.33 b | 85 ± 0.19 b | 0 |
| 1000 | 85 ± 0.28 a | 100 ± 0.77 a | 0 |
| LD50 | 151.5 µgml−1 | 92.22 µgml−1 | – |
All values are expressed as mean ± standard deviation (n = 3) p ≤ .05, LSD critical value for ethyl acetate 1.05 and 2.20 for n-hexane.
Antioxidant activity of ethyl acetate and n-hexane extracts.
| Sample | Concentration (µgml−1) | %RSA | |
|---|---|---|---|
| Ethyl acetate | n-Hexane | ||
|
| 25 | 51.07 ± 0.02 c | 44.94 ± 0.18 d |
| 50 | 62.56 ± 0.10 b | 51.05 ± 0.20 c | |
| 75 | 70.43 ± 0.04 a | 58.98 ± 0.26 b | |
| 100 | 75.03 ± 0.15 a | 65.03 ± 0.09 a | |
All values are expressed as mean ± standard deviation (n = 3) p ≤ .05, LSD critical value for ethyl acetate 5.64 and 1.07 for n-hexane.
Figure 4.Percent Protection against ethyl acetate extract of P. claviforme at different concentrations.
Antinociceptive effect of P. claviforme in the mouse abdominal constriction test.
| Treatment | Dose (mgkg−1) | Number of writhes | Percentage inhibition (%) |
|---|---|---|---|
| Vehicle | 10 | 32.83 ± 2.664 | 1.183 ± 1.520 |
| Diclofenac | 50 | 5.833 ± 1.276*** | 81.24 ± 4.637*** |
|
| 50 | 9.833 ± 2.548*** | 70.15 ± 7.247*** |
|
| 150 | 6.167 ± 1.249*** | 80.43 ± 4.701*** |
Data expressed as a mean number of writhes and percentage inhibition (%) ± SEM. ***P ˂ .001, as compared to the vehicle-treated animals group. One-way ANOVA followed by Dunnett’s post hoc test, n = 6 mice per group.
Acute toxicity of ethyl acetate extract of P. claviforme.
| Treatment | Dose (mgkg−1) | Replication | Time interval (h) | Number of mice died |
|---|---|---|---|---|
| Negative | 10 | 1 | 72 | 0/5 |
|
| 10 | 1 | 72 | 0/5 |
| 15 | 2 | 72 | 0/5 | |
| 20 | 3 | 72 | 0/5 |
Figure 5.(A) 3 D structure of COX-2 (B) 2 D (C) 3 D interactions of L5 with COX-2.
Docking details of mycocompounds (L1-L14) against COX-2.
| Ligands | Binding energy (Kcalmol−1) | Number of interactions | Nature of interactions | Interaction distance (A0) | Interacting residues |
|---|---|---|---|---|---|
| L1 | −4.8130 | 02 | pi-H | 4.46 | Tyr123 |
| pi-H | 3.84 | Phe372 | |||
| L2 | −5.7850 | 03 | pi-H | 4.29 | Asp126 |
| pi-H | 4.43 | Asp126 | |||
| pi-H | 3.84 | Ser127 | |||
| L3 | −6.4789 | 01 | H-acceptor | 2.91 | Arg61 |
| L4 | −7.0675 | 01 | H-donor | 3.29 | Tyr123 |
| L5 | −9.4502 | 03 | H-donor | 2.80 | Thr62 |
| H-donor | 2.79 | Ser127 | |||
| H-acceptor | 2.96 | Ser127 | |||
| L6 | −6.8173 | 03 | H-donor | 2.96 | Asp126 |
| H-donor | 2.81 | Tyr123 | |||
| H-acceptor | 3.14 | Ser127 | |||
| L7 | −7.9987 | 03 | H-donor | 2.87 | Ile125 |
| H-donor | 2.72 | Lys469 | |||
| H-acceptor | 3.16 | Ser127 | |||
| L8 | −6.6080 | 02 | H-acceptor | 2.98 | Ser472 |
| H-acceptor | 3.02 | Arg44 | |||
| L9 | −5.8384 | 02 | H-donor | 3.03 | Asn43 |
| H-donor | 2.95 | Lys469 | |||
| L10 | −5.1519 | 02 | H-donor | 2.98 | Asn43 |
| H-donor | 3.31 | Lys469 | |||
| L11 | −4.4126 | 03 | H-acceptor | 3.00 | Arg61 |
| H-acceptor | 3.17 | Arg61 | |||
| Ionic | 3.39 | Arg44 | |||
| L12 | −5.0901 | 02 | H-donor | 2.90 | Tyr123 |
| H-acceptor | 3.02 | Ser127 | |||
| L13 | −6.0370 | 02 | H-donor | 3.21 | Arg44 |
| H-acceptor | 3.17 | Ser127 | |||
| L14 | −6.4842 | 01 | H-acceptor | 3.08 | Arg61 |
L1 = Quinoline, L2 = N-(6-Oxo-6H-dibenzo[b,d]pyran-3-yl)acetamide, L3 = 5,8-tetradecadienal, L4 = Cetrimonium, L5 = Kurilensoside F, L6 = 3β,15β,17α-trihydroxy-pregnenone, L7 = 5S-HETE di-endoperoxide, L8 = Obtusin, L9 = 4,4′-Diaminostilbene, L10 = Amobarbital, L11 = 4-(Trimethylammonio)but-2-enoate, L12 = Fraxetin, L13 = Maculosin, L14 = Onchidal
Figure 6.(A) 2 D (B) 3 D interactions of L7 with COX-2.